Summit Therapeutics Announces Phase III Trial HARMONi-2 Meets Primary Endpoint Of Progression-Free Survival For Ivonescimab In Advanced NSCLC With PD-L1 Expression
Merck & Co., Inc. +0.28%
Summit Therapeutic +0.44%
Merck & Co., Inc. MRK | 106.64 | +0.28% |
Summit Therapeutic SMMT | 20.59 | +0.44% |
- Unprecedented: Ivonescimab Is the First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab in Randomized Phase III Clinical Trial in NSCLC
- Monotherapy Ivonescimab Achieved Clinically Meaningful PFS Benefit in HARMONi-2 Trial Conducted by Akeso
- PFS Improvement Was Observed Broadly in Patients Across Subgroups, including PD-L1 Low and PD-L1 High Expressing Tumors, Squamous and Non-Squamous Histologies
- Full Data Set to be Presented at an Upcoming Major Medical Conference Planned for Later This Year
